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Introduction: Thimerosal (or Thiomersal) is a trade name for an organomercurial compound (sodium ethyl-
mercury (Hg) thiosalicylate) that is 49.55% Hg by weight, which rapidly decomposes in aqueous saline solutions
into ethyl-Hg hydroxide and ethyl-Hg chloride. Developed in 1927, it has been and is still being used as a preser-
vative in some cosmetics, topical pharmaceuticals, and biological drug products, including vaccines. Concerns
have been voiced about its use because it is toxic to human cells. Although it is banned in several countries, it
continues to be added to some vaccines in the United States and many vaccines in the developing world.
Discussion: This critical review focuses on the clinical, epidemiological, and biochemical studies of adverse effects
from Thimerosal in developing humans. This review will include research that examines fetal, infant, and
childhood death; birth defects; neurodevelopmental testing deﬁcits in children; and neurodevelopmental
disorders (attention deﬁcit/hyperactivity disorder, autism spectrum disorder, tic disorder, and speciﬁc develop-
mental delays). The review will also look at the research that examined the outcomes of acute accidental ethyl-
Hg poisoning in humans. The studies that examine the underlying biochemical insights into the neuronal cellular
damage will also be explored.
Conclusion: The culminationof the research that examines the effects of Thimerosal in humans indicates that it is a poi-
son atminute levelswith a plethora of deleterious consequences, even at the levels currently administered in vaccines.© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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Thimerosal (or Thiomersal) is a trade name for an organomercurial
compound (sodium ethyl-mercury (Hg) thiosalicylate, C9H9HgNaO2S)
that is 49.55% Hg by weight. Thimerosal quickly decomposes in aqueous
saline solutions into ethyl-Hg hydroxide and ethyl-Hg chloride [1].
Developed in 1927, it has been used as a preservative in cosmetics, phar-
maceutical preparations, and biological products such as eye shadows,
make-up removers, mascaras, and soap-free cleansers (cosmetic prod-
ucts); ear, eye and nose drops and ointments, antiseptic sprays, topical
medications and tincture of Merthiolate (pharmaceutical preparations);
and antitoxins, immune globulin preparations, skin-prick test antigens,
and vaccines (biological products) [2].
Hg compounds have been used as disinfectants since bacteriology
began [3]. For a long period of time, Hg compounds, such as mercury
chloride (HgCl2), were thought to be useful in the killing of bacteria
and other microorganisms [3]. Despite this fact, as early as 1943, it was
reported that plasma preserved with 1:10,000 Thimerosal was contami-
nated with viable micro-organisms, and it was concluded that Thimero-
sal cannot be considered the ideal preservative [4]. Subsequently,
Morton et al. [3] reported that the label for Thimerosal (solution of
1:1000) stated that Thimerosal is a stainless and stable organic mercury
compound of high germicidal value, especially in serum and other pro-
tein media. However, Morton et al. [3], based upon their experiments,
found that Thimerosal is not highly germicidal and does not possess
high germicidal value in the presence of serum and other protein
mediums particularly. They further stated that the loss of antibacterial
activity ofmercurials in the presence of serumproves their incompatibil-
ity with serum. Furthermore, these investigators described that Thimer-
osal was 35-times more toxic to embryonic tissue cells than it was to
bacteria, as well as more toxic to leukocytes than bacteria [3].
Inmore recent research, the effectiveness of Thimerosal as a preserva-
tive in Diphtheria–Tetanus–Pertussis (DTP) vaccine was evaluated by the
United States (US) Centers for Disease Control and Prevention (CDC) [5].
The CDC reported that the choice and level of the preservative for
inclusion in DTP vaccine were limited because of possible harmful
effects on the vaccine's antigenicity, plus the need to ensure safety of
the preservative. These investigators reported that Thimerosal, the
preservative used in the productionofDTP as anorganic-Hg bacteriostatic
agent, was onlyweakly bactericidal. The laboratory experiments revealed
up to 2-week survival of bacterial cells in multi-dose DTP vaccine vials
using Thimerosal as a preservative. These investigators concluded that
at currently used concentrations, Thimerosal is not an ideal preservative.
Higher concentrations were not recommended because it might reduce
vaccine potency or pose a danger to individuals receiving the vaccine.
As a result, the investigators suggested that those administering Thimer-
osal preserved vaccines should not rely on its effectiveness, but instead
should apply particular attention to sterile technique when using multi-
dose vials. Other investigators observed that Thimerosal failed to meet
European Pharmacopoeia (EP) antimicrobial effectiveness acceptance
criteria as a preservative due to lack of growth inhibition of Thimerosal
on Staphylococcus aureus in both single and multi-challenge evaluations
[6]. Finally, other investigators described the toxicity levels of commonly
used preservatives in vaccines and biologics [7]. When comparing the
relative cytotoxicity levels of the preservatives in US licensed vaccines,
the observed relative toxicity of the compounds tested was phenol b 2-
phenoxyethanol b benzethonium chloride b Thimerosal, and the relative
toxicity indices (human neuroblastoma cells/bacterial cells) were 2-
phenoxyethanol (4.6-fold) b phenol (12.2-fold) b Thimerosal (N330-
fold). For the products tested, except for 2-phenoxethanol, the amounts
needed to cause signiﬁcant killing of bacteria were much higher than
those routinely used in US licensed vaccine/biological preparations.
Despite all of the aforementioned concerns and the fact that there
are other approved and effective preservatives available [6,7], Thimero-
sal continues to be used as a preservative in several vaccines to date and
is a considerable source of Hg exposure for children [8,9]. About 50% ofthe Hg exposure in infants comes from the recurring bolus doses of
Thimerosal from Thimerosal-containing vaccines administered in the
ﬁrst 2 years of life (cumulative doses of Hg exposure from Thimerosal-
containing vaccines can be as high as 187.5 μg Hg in the ﬁrst six months
of life) [9]. Although this degree of exposure in theﬁrst sixmonths of life
has been reduced in the US in recent years, it remains unchanged in
developing countries. There is considerable body of scientiﬁc and
medical evidence supporting a role from Hg exposure causing harmful
consequences [10]. To date, there are at least 180 studies that show
harm from Thimerosal [11]. The purpose of this review is to speciﬁcally
examine human clinical, epidemiological, and biochemical studies
demonstrating the developmental adverse affects from human expo-
sure to Thimerosal and its ethyl-Hg breakdown products.
2. Thimerosal exposure from vaccines
Until the beginning of this century, every tetanus-containing vaccine
in the US (e.g., the DTP, tetanus toxoid (TT), diphtheria–tetanus (DT),
and diphtheria–tetanus–acellular-pertussis (DTaP)), Haemophilus inﬂu-
enza type b (Hib), hepatitis B (HepB), and a polysaccharidemeningococ-
cal meningitis A, C, Y, andW-135 vaccine contained Thimerosal, many at
a concentration of 0.01% Thimerosal. However, on July 7, 1999, the US
Public Health Service (USPHS) and American Academy of Pediatrics
(AAP) called for the elimination of Thimerosal from all vaccines in the
US as soon as possible [12]. Then, as the vaccines were approved by the
US Food and Drug Administration (FDA), reduced-Thimerosal vaccines
began to displace the previous Thimerosal-preserved vaccines in the
early 2000s. Finally, beginning in the late 2000s, no-Thimerosal vaccines
began to replace the reduced-Thimerosal vaccines in the US. However, to
date, the US FDA has not canceled the licenses for the Thimerosal-
preserved vaccines or kept them from being produced and marketed
[13].
As more of the reduced-Thimerosal and no-Thimerosal vaccines be-
came available in the early 2000s in theUS, the assumptionwas that the
exposure to Thimerosal would sharply decrease. However, this expecta-
tion proved to not be accurate because of recommendation changes in
the vaccination schedule. Starting in April of 2002, the US CDC began
to recommend that inﬂuenza vaccines be given to infants and children,
who were 6-to-23 months of age, when the only approved inﬂuenza
vaccine for that age group was preserved with Thimerosal (Sanoﬁ
Pasteur's Fluzone®). In addition, the US CDC recommended inﬂuenza
vaccines be given to women who were pregnant in their second and
third trimesters, when the available inﬂuenza vaccines were also
Thimerosal preserved [14]. In addition, through 2010, the US CDC pro-
gressively widened the age range for annual inﬂuenza vaccine such
that very young children were supposed to get two doses of inﬂuenza
vaccine initially (at 6 and 7months of age) and then receive an addition-
al dose every year. By this time, the US CDC had also discontinued the
“second-and-third-trimester” constraint on giving inﬂuenza vaccines
to pregnant women [15–17].
Thus, even though the US FDA eventually approved the reduced-
Thimerosal and no-Thimerosal formulations of the tetanus-containing
vaccines and some other vaccines, exposure to Thimerosal through
vaccination has remained common in the US. As recently as 2013,
more than half of all the inﬂuenza vaccines were still preserved with
Thimerosal. Therefore, the approximate maximum lifetime exposure
to Hg from Thimerosal-preserved vaccines has increased compared to
the lifetime exposure under the US CDC's pre-2000 recommended
vaccination schedule. It is estimated that it is now more than double
what it would have been had the pre-2000 vaccination schedule been
maintained. To date, in the US, Thimerosal is still a preservative in
some of the other US FDA-approved vaccines including a multi-dose
tetanus toxoid (TT) vaccine, and onemulti-dosemeningococcal menin-
gitis vaccine [18]. Estimations suggest that there has not been a major
decrease in Hg exposure from Thimerosal-preserved vaccines in
vaccine-schedule-compliant children in the US.
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pregnant women continues to occur through the use of inactivated-
inﬂuenza vaccine still being given to pregnant women (that was ﬁrst
recommended by the US CDC in 1997) [19], since many of the
inactivated-inﬂuenza vaccines and most of the available doses of those
ﬂu shots still contain Thimerosal [20,21]. To date, the amount of Hg
still present in Thimerosal-preserved vaccines nominally ranges from
12.5 μg Hg to 25 μg Hg per dose (with some vaccines containing
N25 μg Hg per dose) [18].
Globally, and especially in the developing world, Thimerosal is still
used in many of the childhood vaccines such as tetanus toxoid, Hib,
HepB, DTwP–HepB–Hib, DTP, and assorted inﬂuenza and meningococ-
cal vaccines [22–24]. In addition, the tetanus toxoid vaccine (25 μg Hg
per dose) is also recommended for pregnant women in some countries
[25].
In estimating Hg exposure from Thimerosal-containing child-
hood vaccines, it was previously determined by Bigham and Copes
[9] that some infants were exposed to cumulative doses of Hg from
vaccines and environment that were over the Hg safety limits
established by the US FDA, US CDC, US EPA, the World Health Orga-
nization (WHO) and Health Canada. In addition, it was observed
that two-month-old US infants exposed to an average of 45.6 μg Hg
(range 37.5 μg Hg–62.5 μg Hg) from Thimerosal-containing child-
hood vaccines by Pichichero et al. [26] had circulating blood Hg
levels between 3.75 and 20.55 nM. Other researchers reported that
Thimerosal-preserved vaccines given to human infants signiﬁcantly
increased the infants' blood Hg levels. Some of the infants had a
total blood mercury level that was over the safety limit set by the
US Environmental Protection Agency (US EPA) [27–29]. It was also
observed that Thimerosal-containing childhood vaccines given to in-
fants signiﬁcantly increased the hair ethyl-Hg and total Hg levels.
Importantly, some of infants had total hair Hg levels that were over
the safety limit set by the US EPA [30].
3. Thimerosal exposure and fetal/infant/childhood death
Ethically and legally, the direct study of the effects of Thimerosal or
ethyl-Hg compound exposure on fetal/infant/childhood death in
humans is proscribed. On a theoretical basis, a number of previous
researchers have investigated the potential toxicokinetics of Hg expo-
sure fromThimerosal in pregnantwomen [20]. For example asGoldman
[20] showed in his analysis of exposure to Hg from Thimerosal during
pregnancy (assuming 50% of the total dose would accumulate in the
fetus) that administration of a single Thimerosal-preserved inﬂuenza
vaccine (25 μg Hg per dose) in comparison to the US EPA Hg safety
limit would result in a fetus of average weight receiving a Hg dose
that could be≥125,000 times the EPA Hg safety limit if it was adminis-
tered at≤8 weeks of gestation and, by 42weeks of gestation, result in a
fetus of average weight receiving a Hg dose 34 times the EPA Hg safety
limit. It was also determined by Goldman [20], given the aforemen-
tioned assumption that 50% of the total dose would accumulate in the
fetus, that administration of a single Thimerosal-containing inﬂuenza
vaccine with 1 μg Hg per dose in comparison to the US EPA Hg safety
limit would result in a fetus of average weight receiving a Hg dose
≥5000 times the EPA Hg safety limit if it was administered at
≤8 week gestation and, by 42 week gestation, result in a fetus of aver-
age weight receiving a Hg dose 1.4 times the EPA Hg safety limit. Simi-
larly, Brown and Austin [21] evaluated fetal exposure to Hg from one
Thimerosal-preserved inﬂuenza shot during pregnancy (25 μg Hg per
dose). Those investigators modeled exposure assuming hypothetical
placental elimination of Hg at 0% (25 μg Hg exposure), 90% (2.5 μg Hg
exposure), and 99% (0.25 μg Hg exposure). Overall, these investigators
observed that doses of Hg exposure from administration of a single
Thimerosal-preserved inﬂuenza vaccine during pregnancy resulted in
a developing fetus receiving a dose of Hg in excess of the US EPA Hg
safety limit from between 1,000,000 times to 10,000 times that safetylimit at 1 week of development to 7.6 times to 0.1 times that limit at
38 weeks of development. It is interesting to note, from the Brown
and Austin [21] modeling data, that, even assuming 99% elimination of
the Hg dose by the placenta, a developing fetus even at 16 weeks-old
would still receive a dose of Hg greater than 2.5 times the EPA Hg
limit for safety. Overall, both Brown and Austin [21] and Goldman [20]
concluded their toxicokinetic studies by suggesting that, given themag-
nitude in excess of the EPA Hg safety limits presented by exposure to a
dose of Thimerosal-preserved vaccine during pregnancy, it is biological-
ly plausible for such exposures to result in fetal/infant death and devel-
opmental disability.
In addition to toxicokinetic modeling studies of exposure to Thimero-
sal, many observational studies have examined the relationship between
Hg exposure from Thimerosal or its ethyl-Hgcompounds decomposition
products. For example, in the 2009–2010 inﬂuenza season, the US CDC
recommended thatwomenwho are pregnant be administered a seasonal
inactivated-inﬂuenza vaccine dose and a pandemic (A-H1N1-2009)
inactivated-inﬂuenza vaccine dose, encouraged all pregnant women to
get both vaccines, and allowed both vaccines to be administered at the
same time [20]. The inactivated-inﬂuenza vaccine doses available for ad-
ministration included Thimerosal-preserved vaccines, where about 50%
of the available doses of the seasonal inactivated-inﬂuenza vaccine were
Thimerosal-preserved doses; more than 50% of the pandemic
inactivated-inﬂuenza vaccines were Thimerosal-preserved doses; and
the CDC did not recommend that the pregnant women only be given
the Thimerosal-free [20].
During the Fall of 2009, against a background of no more than ﬁve
fetal-loss reports (spontaneous abortions and stillbirths) linked to the
administration of an inﬂuenza vaccine in the Vaccine Adverse-Events
Reporting System (VAERS), the number of fetal-loss reports to VAERS
quickly exceeded 50 reports. By the end of 2009, the reports exceeded
100 fetal-loss instances before ending up at 178 fetal-loss reports in
VAERS for the 2009–2010 ﬂu season. An epidemiological study of the
VAERS data by Goldman [20] that included correction for increased
uptake and increased reporting, observed that there was more than an
8-fold fetal-loss reports increase in the 2009–2010 ﬂu season over the
average reporting rates for the prior (2008–2009) and subsequent
(2010–2011) inﬂuenza seasons (roughly August through April of each
year). Goldman [20] concluded from his analysis that a single
Thimerosal-preserved inﬂuenza vaccine nominally containing 25 μg of
Hg per dose was not sufﬁcient to cause enough fetal-loss reports to
VAERS to be of concern, but that two doses (one from a Thimerosal-
preserved seasonal inﬂuenza vaccine and one from a Thimerosal-
preserved pandemic inﬂuenza shot) were sufﬁcient to generate a
signiﬁcant Thimerosal-exposure-related, fetal-loss-report signal.
As another example, Axton [31] reported about two adults and four
children who were injected (accidently) with abnormally large quanti-
ties of Thimerosal from inappropriately prepared chloramphenicol-
containing preparations. The children (aged between 6 weeks-old and
7 years-old) received between about 35 milligrams (mg) Hg per
kilogram (kg) bodyweight and 162 mg Hg per kg bodyweight. All but
one of them died within about 1 month (mortality rate = 75%).
As yet another example, topical application of Thimerosal to infants
was shown to induce fatalities. Fagan et al. [32] reported on a case-series
of 13 infantswith omphaloceles (protrusions of the intestine and omen-
tum through a hernia in the abdominalwall near the navel) treatedwith
topical 0.1% Thimerosal solutions. It was reported that 10 of the 13
infants treated in this manner subsequently died (mortality rate =
77%), and analysis of Hg levels in their organs showed that the Hg
ranged from65–2700 timesmore than normal levels of Hg in the organs
tested. Furthermore, Rohyans et al. [33] reported on an 18-month-old
female who was administered Thimerosal ear irrigations on a daily
basis for a month, and subsequently died of Hg poisoning.
In addition to fetal/infant/childhood fatalities observed following
Thimerosal exposure, similar consequences were observed following
exposure to its ethyl-Hg decomposition products. Cinca et al. [34]
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poisoned by eating hog meat from hogs that were inadvertently fed
seed treated with ethyl-Hg chloride fungicides. The symptoms of Hg
intoxication began 10 days after exposure, and, overall, it was observed
that 2 of the 3 children (aged between 10 and 15), both boys, died from
Hg poisoning (mortality rate = 67%).4. Thimerosal exposure and birth defects
Under the authority of the US National Institute of Neurological and
Communicative Disorders and Stroke, the largest study to examine the
relationship between Thimerosal exposure in pregnancy and birth
defectswas conducted between 1958 and 1965. The studywas conduct-
ed on a prospective sample of 50,000+womenwhowere pregnant and
their children [35]. This study is important because among 2277
children with malformations showing uniform rates by hospital in
relation to exposure to topical antimicrobial drugs during lunar months
1–4 in 50,282mother and child pairs, the survival and race standardized
relative risk for Thimerosal was statistically signiﬁcantly increased
(2.69-fold). In addition, it was observed that inﬂuenza vaccine (at a
timewhen itwas preservedwith Thimerosal) exposurewas a risk factor
for cleft palate (hospital standardized relative risk= 7.1), microcephaly
(hospital standardized relative risk = 2.6), and pyloric stenosis
(hospital standardized relative risk = 2.0) [35].
In addition, large-scale accidental poisonings of human populations
with ethyl-Hg-based fungicides have provided information on the
ability of in utero ethyl-Hg exposure to induce birth defects [36,37].
These changes (noted in the infants) included: (1) disorders of the
central nervous system (CNS), hydrocephalus, cerebral paralysis, and
spasms; (2) toxic encephalomyeloradiculoneuritis with prevalence of
the syndromes of lesions of the cerebellum, brain stem, cerebral cortex,
myelitis, and peripheral neurites, plus lesions of the motor centers and
the pyramidal tracts, and encephalitis with irregular alpha-rhythm;
(3) epilepsy (lasting up to 2 years) was observed in 10% of all the
cases; (4) vegetoneurotic syndromes, bradycardia, tachycardia,
arrhythmia, acrocyanosis, labile arterial pressure, and reduced blood
cholinesterase activity; and (5) lesions of the heart, liver, kidney, and
gastrointestinal tract.5. Thimerosal and neurodevelopmental testing deﬁcits in children
Recent studies comparing a cohort of infants at six months of age
from communities with different ﬁsh-eating habits (rural communi-
ties in comparison to urban infants) who were simultaneously ex-
posed to methyl-Hg and ethyl-Hg found that urban infants, who
had the highest ethyl-Hg exposure from Thimerosal-containing vac-
cines and relatively lower methyl-Hg in comparison to rural infants,
also had the highest risk of developmental delays (Gesell schedules
below the median) [38]. Interestingly, examining this same cohort
at 60 months of age failed to identify difference in development
based upon Gesell schedules [39]. Finally, among a cohort of infants
with multiple exposures to neurotoxic substances, those showing
the most severe neurodevelopmental delays in psychomotor develop-
mental index scores between six and 24 months of age were the ones
with exposure to higher levels of ethyl-Hg from Thimerosal-
containing vaccines [40].
Other investigators conducted a longitudinal cohort study to
examine the relationship between infant exposure to Thimerosal from
vaccines and child development in the ﬁrst 3 years of life among 196
infants (born 2001–2003) in Krakow, Poland [41]. These investigators
observed a signiﬁcant adverse effect of neonatal exposure to Hg from
Thimerosal on the children's psychomotor development index scores
between the 12th and 24 months of life, and these deﬁcits were
observed to persist during the study's three-year follow-up period.6. Thimerosal and neurodevelopmental disorders (ASD, ADHD,
and TD)
Autism spectrum disorder (ASD), attention deﬁcit/hyperactivity
disorder (ADD/ADHD), and tic disorder (TD) are neurodevelopmental
disorders that typically begin in childhood and are considered chronic
conditions that last a lifetime. In all three disorders, males are affected
more often than females. Shared symptomatology is also reported,
such as problems with attention, social difﬁculties, obsessive compul-
sive behaviors, depression, anxiety, and ritualistic behaviors such as
counting, repeating, or ordering and arranging. There has been a rise
in these neurodevelopmental disorders in the last two decades [42].
However, to date, there is a debate as to the causes or contributing fac-
tors related to the increase. There are several studies that suggest that
Thimerosal exposure in infancy increases the risk of a diagnosis of
ASD, ADHD, and TD. This section will discuss the studies that show a re-
lationship between Thimerosal exposure and ASD, ADHD, and TD.
6.1. Autism spectrum disorder (ASD)
For example, Geier et al. [43] recently undertook a two-phase study
to examine the possible association between Hg exposure from Thimer-
osal in vaccines and the risk for an ASD diagnosis in the US. In the ﬁrst
phase of the study, a hypothesis generating cohort studywas conducted
to examine the possible relationship between exposure to Hg from a
Thimerosal-containing DTaP vaccine in comparison to Thimerosal-free
DTaP vaccines (from 1998 through 2000) and the risk of anASD diagno-
sis in the VAERS database. In the second phase of the study, a hypothesis
testing case–control study in the accessible Vaccine Safety Datalink
(VSD) database was conducted to examine the relationship between
Hg exposure from Thimerosal-containing hepatitis B vaccines given
during speciﬁc time periods in the ﬁrst six months of life among cases
diagnosed with an ASD and controls without such exposures (born
from 1991 through 1999). The results of the ﬁrst phase of the study
revealed a signiﬁcantly increased risk ratio for the incidence of an ASD
diagnosis following the receipt of Thimerosal-containing DTaP vaccine
compared to the receipt of Thimerosal-free DTaP vaccine. In second
phase of the study, cases diagnosed with an ASD were signiﬁcantly
more likely to have received increased Hg from Thimerosal-containing
hepatitis B vaccine doses given within the ﬁrst, second, and sixth
month of life than controls.
In another example, Young et al. [44], examined the relationship
between the birth cohort's prevalence of an ASD diagnosis and the
birth cohort's cumulative exposures to Hg fromThimerosal in childhood
vaccines given from birth to 7 months of age and from birth to
13 months of age among 278,624 subjects (born from 1990–1996) in
the VSD. They used an ecological study design. Young et al. [44], found
a dose–response relationship between increasing Hg exposure from
Thimerosal in childhood vaccines given between birth and 7 months
of age and between birth and 13months of age for the risk of diagnosed
autistic disorder and diagnosed ASD. Infants receiving an additional
100 μg Hg from Thimerosal in childhood vaccines between birth and
7 months of age showed a statistically signiﬁcant increased rate ratio
of 2.87 for an autistic disorder diagnosis and a statistically signiﬁcant
increased rate ratio of 2.44 for an ASD diagnosis.
Similarly, the relationship between administration of Thimerosal-
containing hepatitis B vaccine within the ﬁrst months of life and the
subsequent risk of an individual being diagnosed with an autistic disor-
der was examined by Gallagher and Goodman [45]. They used the Na-
tional Health Interview Survey (NHIS) 1997–2002 data sets. They
reported that boys vaccinated with Thimerosal-containing hepatitis B
vaccine during the ﬁrst month of life were three times more likely to
be diagnosed with autism than boys who were never vaccinated with
that vaccine or boys who were vaccinated after the ﬁrst month of life.
Geier and Geier [46] conducted a meta-analysis using statistical
modeling to examine the relationship between exposure to Hg from
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autism in the VAERS database. In that study, Geier and Geier [46]
found a signiﬁcant (1.6-fold) increased risk of autism adverse-event
report in VAERS following additional doses of Hg from Thimerosal-
containing vaccines.
In addition to postnatal exposure to Hg from Thimerosal in vaccines,
researchers have also examined the relationship between prenatal
exposure to Hg from Thimerosal-containing RhoD immune globulin
preparations and the risk of a child being diagnosed with an ASD. The
hypothesis was that if prenatal RhoD immune globulin preparation
exposure was a risk factor for an ASD diagnosis then more children
with an ASD diagnosis would have Rh-negative mothers as compared
to children with Rh-positive mothers [47]. A previous study reported
that children with an ASD diagnosis were signiﬁcantly (28.30%) more
likely (odds ratio = 2.35, p b 0.01) to have Rh-negative mothers
(14.36%) [48]. In a second study, therewas a comparable and signiﬁcant
increase in Rh-negativemoms among children with a diagnosed ASD at
two separate clinics (clinic A = 28.3%, B = 25.3%) compared to two
separate control groups (clinic A = 12.1%, B = 13.9%) [47]. Supporting
these ﬁndings, Holmes et al. [49] had previously reported that mothers
of children with an autistic disorder were signiﬁcantly more likely to
have been given an increased number of Rho(D) immune globulin
preparation doses than the mothers of unaffected controls.
Finally, investigators have reported on a clinical case-series of eight
children with a diagnosed Hg toxic encephalopathy showing regressive
ASD symptoms following signiﬁcant Hg exposure from Thimerosal-
containing vaccines and Rho(D) immune globulin preparation expo-
sures [50]. The case-series revealed: (1) a consistent pattern of regres-
sive ASD; (2) excretion of signiﬁcant amounts of Hg post-chelation
challenge test; (3) biochemical tests that showed that their glutathione
pathways were compromised (decreased function in their Hg-related
excretion pathways); and (4) no other known signiﬁcant Hg exposures
except from Thimerosal-containing vaccine and Rho(D) immune globu-
lin preparation doses. Moreover, any other cause of their regression had
been ruled-out. In addition, there was a signiﬁcant dose–response
relationship between the total Hg dose received from Thimerosal-
containing vaccine and Rho(D)-immune globulin-preparation expo-
sures and ASD symptom severity. Based upon differential diagnoses, it
was concluded that the eight patients examined had signiﬁcant Hg
exposure from Rho(D) immune globulin preparations and Thimerosal-
containing vaccines during their fetal and infant periods. Subsequently,
these previously normally developing children suffered Hg toxic
encephalopathy (between 12 and 24 months of age) that manifested
with clinical symptoms consistent with a regressive ASD diagnosis.
It is noteworthy that the 2004 Consensus Report issued by the Insti-
tute of Medicine (IOM) failed to ﬁnd an association between vaccines
and autism [51]. The foundation of their conclusion was based upon a
set of statistical population studies that were completed, funded and/
or cosponsored by the United States Centers for Disease Control (US
CDC). These studies include: (1) the Madsen et al. [52] ecological
study of autism incidence in relation to Thimerosal exposure in
Denmark, (2) the Stehr-Green et al. [53] ecological study of autism
incidence in relation to Thimerosal exposure in Denmark, Sweden and
California, (3) the Hviid et al. [54] study of autism incidence in relation
to Thimerosal exposure in Denmark (also ecological), (4) the Andrews
et al. [55] cohort study of autism incidence in relation to Thimerosal
exposure in the United Kingdom, and (5) the published Verstraeten
et al. [56] CDC cohort study of autism incidence in relation to Thimerosal
exposure in the US. Later, the CDC published the Price et al. [57] study of
autism incidence in relation to Thimerosal exposure in the US.
However, a recent review which critically examined these studies
found several methodological issues of concern and, as such, concluded
that their results are uninterpretable [58]. One methodological issue of
concern was a statistical phenomenon called “overmatching” which
was found in the Verstraeten et al. [56] and Price et al. [57] studies.
Overmatching occurs when a matching variable is a signiﬁcantpredictor of exposure. This can artiﬁcially increase the chance that
within-strata exposure is the same [59]. In addition, some of these
studies examined cohorts with signiﬁcantly different childhood vacci-
nation schedules and with different diagnostic criteria for outcomes
than those used in the US. Moreover, these studies used an insufﬁcient
length of time for the follow-up period. Follow-up period is a critical
issue in all studies examining the relationship between exposures and
the subsequent risk of a diagnosis of a neurodevelopmental disorder.
Any follow-up period that fails to take into account the lag-time
between birth and the subject's age of an initial diagnosis will not be
able to observe the true relationship between exposure and outcome.
Many other methodological issues of concern in these studies have
been delineated. For a complete review of the methodological issues
of concern in these aforementioned studies, please see Hooker et al.
[58].
6.2. Attention deﬁcit/hyperactivity disorder (ADD/ADHD)
Several studies, using several epidemiological methods in various
databases, have also shown that Hg exposure from Thimerosal is a risk
factor for ADD/ADHD diagnosis. For example, the aforementioned
Young et al. [44] study observed that Hg exposure from Thimerosal in
childhood vaccines given between birth and 7 months of age and
between birth and 13 months of age was a signiﬁcant dose-dependent
risk factor for an ADD/ADHD diagnosis. Infants who received another
100 μg Hg from Thimerosal in childhood vaccines administered
between birth and 7 months of age were found to have a signiﬁcantly
increased risk ratio (3.15) for diagnosed ADD/ADHD, and infants receiv-
ing another 100 μg Hg from Thimerosal in childhood vaccines adminis-
tered between birth and 13 months of age, showed a signiﬁcantly
increased risk ratio (4.51) for diagnosed ADD/ADHD. Previously, Geier
and Geier [60] conducted a cohort study in the VSD database to evaluate
the relationship between increasing Hg exposure from Thimerosal in
vaccines given within the ﬁrst, second, third, and six months of life
and the risk of an ADD diagnosis. That study reported a dose–response
relationship between increasing cumulative Hg exposures from
Thimerosal-containing vaccines administered within the ﬁrst six
months of life and the eventual risk of child receiving an ADD diagnosis.
Researchers have also examined the relationship between prenatal
exposure to Hg from Thimerosal-containing RhoD immune globulin
preparations and the risk of an ADD/ADHD diagnosis. The hypothesis
was that if prenatal exposure to RhoD immune globulin preparation
was a risk factor for an ADD/ADHD diagnosis then more children with
an ASD diagnosis would have Rh-negative mothers compared to Rh-
positive mothers [47]. Here, the epidemiological study found that
maternal Rh-negativity in children diagnosed with ADD/ADHD in clinic
A (26.3%) was signiﬁcantly increased in comparison to the controls in
both clinics (clinic A = 12.1%, B = 13.9%).
6.3. Tic disorder (TD)
A signiﬁcant association between Hg exposure from Thimerosal-
containing childhood vaccines and diagnosed TD has been found in six
epidemiological studies [44,55,56,60–62]. These studies employed
various epidemiological methods such as case–control or cohort
designs, and were conducted on cohorts of children from several differ-
ent countries. Some were US CDC-sponsored studies and others were
studies conducted by independent investigators. In addition, several of
these studies observed signiﬁcant dose-dependent relationships
between Hg exposure from Thimerosal in vaccines and the risk of diag-
nosed TD. A study byYoung et al. [44], found a dose-dependent relation-
ship between increasingHgexposure fromThimerosal in vaccines given
between birth and 7 months and also between birth and 13 months of
age and the risk of a diagnosed TD. It was observed that, for a 100 μg
Hg difference in exposure between birth and 7 months of age, the risk
for diagnosed TD was signiﬁcantly increased (3.39-fold). For the same
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the risk for diagnosed tics was also found to be signiﬁcantly increased
(4.11-fold). In addition, Geier and Geier [60] conducted a cohort study
in the VSD database to evaluate the relationship between increasing
Hg exposure from Thimerosal in vaccines given within the ﬁrst, second,
third, and six months of life and the risk of TD diagnosis. That study
found a dose–response relationship between increasing cumulative
Hg exposures from Thimerosal in vaccines administered within the
ﬁrst three months of life and the risk of a TD diagnosis.
7. Speciﬁc developmental delays
A number of previous studies have observed that Hg administration
from Thimerosal-containing childhood vaccines was a signiﬁcant risk
factor for speciﬁc delays in development [44–46,56,60]. For example
Young et al. [44], observed a signiﬁcant dose-dependent relationship
between increasingHg exposure fromThimerosal in childhood vaccines
given from birth–7 months and birth–13 months and the risk of a
diagnosis of speciﬁc delay in development. Speciﬁcally, these investiga-
tors observed a signiﬁcantly increased rate ratio of 2.27 for diagnosed
developmental disorder/learning disorder in infants who received
another 100 μg Hg from Thimerosal in childhood vaccines from birth
to 7 months of age. Furthermore, a signiﬁcantly increased rate ratio of
2.91 for diagnosed developmental disorder/learning disorder was
found in infants who received an additional 100 μg Hg from Thimerosal
in childhood vaccines from birth to 13 months of age. Other investiga-
tors, using a cohort study design, examined the relationship between
increasing Hg exposure from Thimerosal in childhood vaccines at 1-,
2-, 3-, and 6-months of age and the eventual risk of being diagnosed
with speciﬁc delays in development [60]. A dose-dependent relation-
ship between increasing cumulative Hg exposures from Thimerosal in
vaccines was found to be associated with an increased risk of diagnosed
unspeciﬁed developmental delay, language delay, and speech delay. As
another example, investigators examined the association between
being given three doses of Thimerosal in hepatitis B vaccine prior to
2000 and the risk of a child being diagnosed with a developmental
disability from age 1–9 years, using the National Health Interview
Survey (NHIS) 1999–2000 dataset [45]. Importantly, boys diagnosed
with a development disability had a signiﬁcantly greater odds ratio
(9-fold) for receiving three doses of Thimerosal-containing hepatitis B
vaccine in comparison to receiving no doses of Thimerosal-containing
hepatitis B vaccine.
Previously, those investigators conducted a meta-analysis using sta-
tistical modeling to examine the association between additional doses
of Hg from Thimerosal in childhood vaccines and neurodevelopmental
disorder adverse event reports in the VAERS database [46]. This study
found a statistically signiﬁcant increased risk of speech disorder, mental
retardation, personality disorder, thinking abnormality, and ataxia
adverse event reports submitted to VAERS after the administration of
additional doses of Hg from Thimerosal in vaccines.
Researchers have also examined the relationship between prena-
tal exposure to Hg from Thimerosal-containing RhoD immune globu-
lin preparations and the risk of a neurodevelopmental disorder
diagnosis (mentioned earlier) [47]. The researchers hypothesized
that if prenatal exposure to RhoD immune globulin preparation was
a risk factor for a neurodevelopmental disorder then more children
with a neurodevelopmental disorder diagnosis would have Rh-
negative mothers in comparison to children with Rh-positive
mothers; and (2) if Thimerosal in the RhoD immune globulin prepa-
rations was the component associated with a neurodevelopmental
disorder diagnosis, then the frequency of maternal Rh-negativity in
children with a diagnosed neurodevelopmental disorder should be
similar to control populations following the removal of Thimerosal
from all manufactured RhoD immune globulin preparations from
2002 in the US. The researchers reported that children diagnosed
with a neurodevelopmental disorder (clinic A = 24.2%) had asigniﬁcant increase in maternal Rh-negativity in comparison to con-
trols (clinic A = 12.1%, B = 13.9%). In addition, among children with
a neurodevelopmental disorder diagnosis, born post-2001, a mater-
nal Rh-negativity frequency (13.6%) comparable to that reported
for the controls was observed [47].
8. Outcomes of acute ethylmercury poisoning in children
As discussed previously there have been numerous acute ethyl-Hg
accidental poisonings of children around the world [63,64]. It was
observed from these ethyl-Hg poisonings that adults have a higher
survival rate than children [64] because children are more vulnerable
to toxic metal poisoning [65]. For example, it was described in the
1960 Iraq ethyl-Hg poisoning episode that initially in February 1960,
six members of a single family from Mhanawiya, Middle Euphrates
district, were admitted to the Teaching Hospital, Baghdad, all with
generalized weakness, tiredness, tremor, unsteadiness, dysarthria, and
gastrointestinal symptoms. The family reported that 3 children, aged
6, 8, and 11 years-old, members of the same family, were stricken
with the same symptoms and died at home before the rest of the family
were admitted to thehospital [64]. Subsequently, investigators reported
that, between February and April 1960, an estimated 1000 patientswith
ethyl-Hgpoisoningwere admitted to hospitals all over Iraq, and thepre-
dominant symptoms were those of the nervous system, although
psychiatric disturbances and renal, cardiovascular, respiratory, and
cutaneous manifestations were also present. Reportedly, about 200
patients died from the effects of poison [64]. As described by other
investigators in more detail [66], numerous children between the ages
of 7–18 were poisoned by ethyl-Hg. The symptoms of intoxication
included gastrointestinal symptoms, ataxia, vision abnormalities,
tremors, reﬂex abnormalities, and psychiatric symptoms. In an ethyl-
Hg poisoning episode in Romania [34], the clinical outcomes showed
that it was exceptionally toxic for the brain, spinal motoneurons,
peripheral nerves, myocardium, and skeletal muscles. In China, forty-
one people were poisoned by the ingestion of rice that had been treated
with ethyl-Hg chloride [67]. It was reported that a signiﬁcant number of
children were impacted, and the consequences of exposure were dose-
dependent (the lowest doses of ethyl-Hg exposure with adverse conse-
quences were within about 10-fold of those administered to infants
within the ﬁrst 6 months of life as part of the routine childhood vaccine
schedule in the US in the 1990s). In rural Ghana, 144 cases of ethyl-Hg
poisoning were reported in 1974 [68]. The cases had eaten maize that
was intended for sowing which was dressed with ethyl-Hg chloride.
All showed clinical features typical of alkyl-Hg poisoning, and 20 indi-
viduals died. Children were more affected than adults in the poisoning,
and symptoms in the children included speech disturbances, including
complete lack of speech. Paralysis was seen, as well as mental issues
and behavioral outbursts.
9. Biochemical insights into neuronal cellular damage
With a wide-range of human clinical and epidemiological studies
revealing harmful consequences, especially neurological damage, in
fetuses/infants/children from exposure to Thimerosal and its ethyl-Hg
decomposition products, it is crucial to understand the biochemical
basis for these compounds to induce cellular toxicity. As a result,
human tissue culture studies are important to elucidate the biochemical
mechanisms involved in cellular dysfunction and damage caused by
Thimerosal and its ethyl-Hg decomposition product in humans, and
also provide further insight into the speciﬁc uptake of these compounds
within human cells following exposure.
Several studies have collectively shown that Thimerosal concentra-
tions at nanomolar (nM) to low micromolar (μM) levels are acutely
toxic to human neuronal cells in vitro [69–74]. For example, human
neuroblastoma apoptosis has been reported to occur at levels as low
as 25 nM [69]. Parran et al. [71] reported Thimerosal concentrations
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4.35 nM for 24- and 48-hour incubation periods, respectively.
Other investigators revealed that Thimerosal exposure signiﬁcantly
impacted the neuronal developmental process in vitro. For example,
in a functional test based on the migration of human neural crest cells,
investigators described an examination of developmental toxicants
and signaling pathways [75]. These investigators described that im-
paired neural crest function is a known cause for teratologic effects
and that testing a toxicant's effects should include testing the toxicant's
effect on neural crest cells. After generating neural crest cells from
human embryonic stem cells, and after establishing a migration assay
of neural crest cells, the investigators tested environmental toxicants
and inhibitors of physiological signal transduction pathways. These
investigators observed that 1 nM concentrations of Thimerosal had a
signiﬁcant impact on their human neurodevelopmental model system,
and when this value was compared to the lowest concentrations of
other well-established neurodevelopmental toxins to induce a signiﬁ-
cant impact on their human neurodevelopmental model system,
Thimerosal was more toxic than Pb acetate (about 1000-fold), methyl-
Hg chloride (about 5-fold), HgCl2 (about 50,000-fold), or valproic acid
(about 1000-fold).
As another example, investigators evaluated the activation of methi-
onine synthase by insulin-like growth factor-1 (IGF-1) as well as
dopamine as a target for neurodevelopmental toxins [76]. These inves-
tigators described that methylation activity is important for the ability
of growth factors to encourage normal development, and since
neurodevelopmental toxins interrupt growth factor signaling, they
may exert adverse effects on methylation. These investigators reported
that in human neuroblastoma cells, IGF-1 and dopamine stimulated
methionine synthase activity and folate-dependent methylation of
phospholipids via a PI3-kinase- and MAP-kinase-dependent mecha-
nism. Again, these investigators observed that a 10 nM concentration
of Thimerosal completely eliminated IGF-1 and dopamine stimulated
human neuroblastoma methionine synthase activity, and when this
value was compared to the concentrations of other well-established
neurodevelopmental toxins, Thimerosal was more toxic than PbNO3,
HgCl2, ethanol, or CuCl.
Other investigators examined the ability of Thimerosal (at concentra-
tions comparable to the levels in vaccines to infants) to induce an in vitro
neurodevelopmental model system of the brain's pathological features
observed in neurodevelopmental disorders such as ASD [70]. Overall, it
was concluded that the effects caused by Thimerosal effects were
consistentwith the brain pathology found in ASD. For example, it was ob-
served that the brain sample images from individuals with an ASD were
virtually identical to the pathology found in the co-cultures of
neuronal cells that were exposed to Hg. As another example, it was
observed that the underlying neuronal cell damage caused by Thimerosal
involved mitochondrial dysfunction and impaired oxidative-reduction.
Importantly, studies have identiﬁed evidence for mitochondrial dysfunc-
tion and impaired oxidative-reduction in individualswith anASDdiagno-
sis [10].
A series of recent studies have also evaluated the vulnerability of
individualswith anASD diagnosis to the toxic adverse effects of Thimer-
osal. For example, investigators examined the cellular andmitochondri-
al glutathione redox imbalance in lymphoblastoid cells (LCLs) obtained
from children with an ASD diagnosis [77]. These investigators reported
that the redox ratio of reduced glutathione to oxidized glutathione was
decreased. In addition, in the ASD individuals, the percentage of
oxidized glutathione was increased in both cytosol and mitochondria.
Moreover, Thimerosal exposure resulted in a greater decrease in the
reduced glutathione to oxidized glutathione ratio and an increase in
free radical generation, in the cells from the individuals with an ASD
as compared to the controls. These investigators reported that LCLs
from individualswith anASDhave a reduced glutathione reserve capac-
ity in both cytosol and mitochondria that can limit antioxidant defense
and detoxiﬁcation capacity under pro-oxidant conditions.In addition to this previouswork, researchers recently examined the
action of low levels, ≤1000 nM, of Thimerosal on immortalized B-cells
taken from: (1) subjects diagnosed with an ASD, (2) their fraternal
twins, a sibling, and (3) controls who were age/sex matched to the
cases [78]. It involved eleven families and their matched controls. The
effects of Thimerosal on cell proliferation and mitochondrial function
from the B-lymphocytes were examined. In a subpopulation of eight in-
dividuals (4 diagnosedwith anASD, 2 twins, and 2 siblings) from four of
the families, Thimerosal hypersensitivity was found; however, none of
the matched control individuals showed this response. The cells that
were hypersensitive to Thimerosal also had higher levels of oxidative
stress markers, oxidant generation, and protein carbonyls. The study
also found that mitochondria are the target organelle conferring
Thimerosal sensitivity in the hypersensitive cells. Remarkably, the
quantity of Thimerosal necessary to hinder cell proliferation in the
cases was only 40% of that necessary to hinder cell proliferation in the
matched controls.
In studies that have examined the distribution of Hg species within
the body following Thimerosal-containing vaccine exposure, researchers
have shown that ethyl-Hg species are transported across neuronal cellular
membranes to the same degree as methyl-Hg species [79,80]. Moreover,
both ethyl-Hg and methyl-Hg species were shown to be actively
transported by the L-type neutral amino acid carrier transport (LAT)
system into neuronal cells at the same rate [79]. Overall, the reported
results were that ethyl-Hg partitions at a 5.6-fold greater concentration
within a neuronal cell than outside, and within the cell, ethyl-Hg will
partition by a factor of 1000-fold within the mitochondria [78].
10. Conclusion
Even though the research evidence regarding the toxicity of Thimer-
osal is, as seen in this review of the scientiﬁc literature from over eight
decades of study, substantial, the issue on Thimerosal safety remains
under debate. For example, the WHO's ofﬁcial statement [81] on the
Thimerosal use in vaccines is “It is important to note that concerns
about the toxicity of Thiomersal are theoretical and that there is no
compelling scientiﬁc evidence of a safety problem related to its use in
vaccines, although public perception of risk has been reported in some
countries.” However, the culmination of the research that examines
the effects of Thimerosal in humans indicates that it is a poison at
minute levels with a plethora of deleterious consequences, and there
is a clear cause for concern.
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